ADA urges new US Congress to ok diabetes health coverage

22 December 2006

The American Diabetes Association has called on the 110th US Congress to address as a matter of urgency, what it sees as the "inadequate research and prevention funding in 2007."

The outgoing Congress adjourned without passing those aspects of the health budget dealing with diabetes health coverage and stem cell research, both of which are considered vital by the ADA to "stemming the diabetes epidemic."

The failure of the 109th Congress to pass a budget at the end of the current year meant that President George W Bush's proposed cut of $11.0 million to diabetes research at the National Institutes of Health and additional funding reductions at the Centers for Disease Control and Prevention (CDC) were not enacted. The current majority Republicans refused to enact several areas of the budget in order to force the new Democratic party majority to take harder decisions in the new year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight